Bifogade filer
Conference call regarding Interim Report Q3
Kurs
-0,48%
Likviditet
9,94 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2026-02-19 | 07:30 | Bokslutskommuniké 2025 |
| 2025-11-13 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-14 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-19 | 07:30 | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-17 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-19 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2023-05-17 | - | Årsstämma |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-22 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-13 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2022-05-12 | - | Årsstämma |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-08-16 | - | Extra Bolagsstämma 2021 |
| 2021-05-14 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2021-05-12 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-25 | - | Split SUS 1:5 |
| 2020-05-07 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2020-05-06 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-07-17 | - | Extra Bolagsstämma 2019 |
| 2019-05-10 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-11-21 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-23 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2018-05-22 | - | Årsstämma |
| 2018-05-22 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-17 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Invitation to attend Surgical Science's conference call regarding presentation of the interim report July-September 2023. The presentation will be held in English.
Time: Thursday, November 9 at 11:00 a.m. CET
If you wish to participate via webcast, please use the link below. It will be possible to ask written questions via the webcast.
https://tv.streamfabriken.com/surgical-science-q3-report-2023
If you wish to participate via teleconference, please register via the link below. After registration, you will receive phone numbers and a conference ID to access the conference. It will be possible to ask oral questions via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=5004338
Participants from Surgical Science are:
Gisli Hennermark, CEO
Anna Ahlberg, CFO
A press release with Surgical Science's interim report for July-September 2023 will be published on November 9, 2023 at 07:30 a.m. CET.
Prior to the start of the conference call, presentation material will be available on the company's website, under Investors, Presentations.
Gothenburg, Sweden, October 25, 2023
Surgical Science Sweden AB (publ)
The press release, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
For further information, please contact:
Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com
Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com
About Surgical Science Sweden AB (publ)
One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.
Surgical Science has approximately 260 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Tel Aviv, Israel, as well as in Stockholm, Sweden and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.